Sanofi ADR (SNY)vsTeck Resources Ltd Class B (TECK)
SNY
Sanofi ADR
$46.03
+1.97%
HEALTHCARE · Cap: $109.03B
TECK
Teck Resources Ltd Class B
$50.36
+3.71%
BASIC MATERIALS · Cap: $23.82B
Smart Verdict
WallStSmart Research — data-driven comparison
Sanofi ADR generates 334% more annual revenue ($46.72B vs $10.76B). SNY leads profitability with a 16.7% profit margin vs 13.0%. TECK appears more attractively valued with a PEG of 0.96. TECK earns a higher WallStSmart Score of 73/100 (B).
SNY
Hold49
out of 100
Grade: D+
TECK
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-89.7%
Fair Value
$24.79
Current Price
$46.03
$21.24 premium
Margin of Safety
+37.4%
Fair Value
$96.41
Current Price
$50.36
$46.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Generating 1.6B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 32.6%
Growing faster than its price suggests
Earnings expanding 42.5% YoY
Areas to Watch
2.4% earnings growth
ROE of 6.7% — below average capital efficiency
Expensive relative to growth rate
Grey zone — moderate risk
ROE of 4.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.7% and operating margin at 14.3%.
Bull Case : TECK
The strongest argument for TECK centers on Price/Book, Operating Margin, PEG Ratio. PEG of 0.96 suggests the stock is reasonably priced for its growth.
Bear Case : SNY
The primary concerns for SNY are EPS Growth, Return on Equity, PEG Ratio.
Bear Case : TECK
The primary concerns for TECK are Altman Z-Score, Return on Equity.
Key Dynamics to Monitor
SNY profiles as a mature stock while TECK is a value play — different risk/reward profiles.
TECK carries more volatility with a beta of 1.53 — expect wider price swings.
TECK is growing revenue faster at 9.8% — sustainability is the question.
SNY generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
TECK scores higher overall (73/100 vs 49/100). Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Teck Resources Ltd Class B
BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA
Teck Resources Limited is dedicated to exploring, acquiring, developing and producing natural resources in Asia, Europe and North America. The company is headquartered in Vancouver, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?